Rocket Pharmaceuticals Inc RCKT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RCKT is a good fit for your portfolio.
News
-
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
-
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
-
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?
-
Thinking about trading options or stock in Snowflake, Palantir Technologies, Rocket Pharmaceuticals, Fortinet, or Marathon Digital?
-
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
-
FDA Extends Review of Rocket Pharma's Proposed Kresladi
-
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
-
Rocket Pharmaceuticals Stock Surges 34% on FDA Alignment for Danon Disease Treatment
Trading Information
- Previous Close Price
- $23.63
- Day Range
- $21.96–23.13
- 52-Week Range
- $14.89–32.53
- Bid/Ask
- $18.00 / $22.58
- Market Cap
- $2.00 Bil
- Volume/Avg
- 957,992 / 729,433
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 268
- Website
- https://www.rocketpharma.com
Comparables
Valuation
|
Metric
|
RCKT
|
CBAY
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.34 | 12.65 | 2.91 |
Price/Sales | — | 111.01 | 1,810.15 |
Price/Cash Flow | — | — | — |
Price/Earnings
RCKT
CBAY
VRDN
Financial Strength
|
Metric
|
RCKT
|
CBAY
|
VRDN
|
|---|---|---|---|
Quick Ratio | 7.69 | 10.70 | 17.93 |
Current Ratio | 7.80 | 10.96 | 18.26 |
Interest Coverage | −138.48 | −5.27 | −137.76 |
Quick Ratio
RCKT
CBAY
VRDN
Profitability
|
Metric
|
RCKT
|
CBAY
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | −38.11% | −30.06% | −42.76% |
Return on Equity (Normalized) | −43.04% | −51.97% | −82.42% |
Return on Invested Capital (Normalized) | −43.72% | −30.87% | −50.70% |
Return on Assets
RCKT
CBAY
VRDN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Grwhttdk | Thhz | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fgfxhfxb | Rmskmk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zslbwhf | Nzwnbd | $97.8 Bil | |
MRNA
| Moderna Inc | Zpfsfffh | Tfpmq | $38.8 Bil | |
ARGX
| argenx SE ADR | Sysxppkds | Hwrpw | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Dtrckfkt | Ycfh | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dgnvbzckg | Ybxcx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yzwwyhlyd | Wqfxcd | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fkwzsflbvs | Wbkbk | $12.5 Bil | |
INCY
| Incyte Corp | Fqghbpxnl | Mdtld | $11.5 Bil |